Table 1.
Baseline characteristics of Dutch patients in the XANTUS study (n = 899)
| Age (years), mean ± SD | 69.2 ± 8.9 | |
|---|---|---|
| ≥75, n (%) | 254 (28.3%) | |
| Gender (male), n (%) | 583 (64.8%) | |
| Weight (kg), mean ± SD | 85.8 ± 17.1 | |
| Creatinine clearance (ml/min), n (%) | ||
| 15–29 | 5 (0.6%) | |
| 30–49 | 48 (5.3%) | |
| ≥50 | 527 (58.6%) | |
| Missing | 319 (35.5%) | |
| Atrial fibrillation type, n (%) | ||
| First diagnosed | 170 (18.9%) | |
| Paroxysmal | 473 (52.6%) | |
| Persistent | 98 (10.9%) | |
| Permanent | 158 (17.6%) | |
| CHADS2 score, median (IQR) | 1 (1–2) | |
| <2 | 556 (61.8%) | |
| ≥2 | 343 (38.2%) | |
| CHA2DS2-VASc score, median (IQR) | 2 (2–4) | |
| HAS-BLED score, median (IQR) | 2 (1–2) | |
| ≥3 | 161 (17.9%) | |
| Prior stroke/TIA/non-CNS SE, n (%) | 107 (11.9%) | |
| Congestive heart failure, n (%) | 58 (6.5%) | |
| Hypertension, n (%) | 550 (61.2%) | |
| Coronary artery disease, n (%) | 93 (10.3%) | |
| Peripheral artery disease, n (%) | 47 (5.2%) | |
| Diabetes mellitus, n (%) | 143 (15.9%) | |
| Prior use of antithrombotic therapy, n (%) | 779 (86.7%) | |
| VKA | 559 (62.2%) | |
| Direct thrombin inhibitor | 14 (1.6%) | |
| ASA | 120 (13.3%) | |
SD standard deviation, BMI body mass index, IQR interquartile range, TIA transient ischaemic attack, CNS central nervous system, SE systemic embolism, VKA vitamin K antagonist, ASA acetylsalicylic acid
Creatinine clearance calculated using the Cockcroft-Gault formula